Research has been very varied , however , daily consumption of green tea with doses of EGCG between 100 and 460 mg/day has shown greater effectiveness on body fat and body weight reduction in intervention periods of 12 weeks or more .
In addition , the use of caffeine doses between 80 and 300 mg/day has been shown to be an important factor for this effects , when the participants did not have a high caffeine intake ( > 300 mg/day ) prior to the intervention
The prevalence and incidence of overweight and obesity worldwide continues to increase , as well as diseases related to these conditions .
This is attributed to an increase in energy intake and a decrease in energy expenditure .
Consumption of green tea has been linked to a reduction in body fat and body weight .
However , research on green tea has been very diverse .
This review assesses the investigations that have been made with green tea and its epigallocatechin gallato ( EGCG ) content , evaluating its effect on body fat and body weight in humans .
Health effects of green tea catechins in overweight and obese men: a randomised controlled cross-over trial.
Regular consumption of green tea may be cardioprotective . In the present study we investigated the health effects of dietary supplementation with green tea catechins and the potential modifying effect of the catechol-O-methyltransferase ( COMT ) Val/Met genotype . Subjects ( sedentary males , aged 40 - 69 years , with BMI ≥ 28 and ≤ 38 kg/m(2 ) ) were r and omly assigned to consume decaffeinated green tea extract ( DGT ; 530 mg containing about 400 mg total catechins/capsule , twice daily ) and placebo in a complete cross-over design . Ambulatory blood pressure and biomarkers of metabolic function ( cholesterol , TAG , glucose and insulin ) were measured at weeks 0 and 6 . Although a marked increase in the concentration of plasma epigallocatechin gallate ( EGCG ) , urinary epigallocatechin ( EGC ) and urinary 4'-O-methyl EGC was found after DGT treatment , no effect on blood pressure or biomarkers of metabolic function was observed . However , a period × treatment interaction ( P < 0·05 ) was detected for body-weight change . Despite a similar increase in estimated energy intake during intervention period 1 , body weight decreased by 0·64 ( sd 2·2 ) kg and increased by 0·53 ( sd 1·9 ) kg in the DGT and placebo groups , respectively ( P = 0·025 ) , suggesting a protective effect of green tea catechins on weight gain . Additionally , the COMT Val/Met genotype influenced urinary accumulation of EGC and 4'-O-methyl EGC ( P < 0·01 ) . Mean concentrations were lower in individuals homozygous for the high-activity G-allele , possibly reflecting increased metabolic flux and a more rapid conversion to downstream metabolic species , compared with individuals carrying at least one copy of the low-activity A-allele . Additional studies are needed to confirm these findings and further explore the modifying effect of genotype
Research has been very varied , however , daily consumption of green tea with doses of EGCG between 100 and 460 mg/day has shown greater effectiveness on body fat and body weight reduction in intervention periods of 12 weeks or more .
In addition , the use of caffeine doses between 80 and 300 mg/day has been shown to be an important factor for this effects , when the participants did not have a high caffeine intake ( > 300 mg/day ) prior to the intervention
The prevalence and incidence of overweight and obesity worldwide continues to increase , as well as diseases related to these conditions .
This is attributed to an increase in energy intake and a decrease in energy expenditure .
Consumption of green tea has been linked to a reduction in body fat and body weight .
However , research on green tea has been very diverse .
This review assesses the investigations that have been made with green tea and its epigallocatechin gallato ( EGCG ) content , evaluating its effect on body fat and body weight in humans .